Therapeutic Antibody–IgM Binding for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to modulating antibody therapies for autoimmune diseases are inadequate, as they often rely on transgenic mouse models that do not accurately represent human autoimmune diseases and fail to consider the role of natural polyreactive IgM antibodies in autoimmunity.
Innovation Solution
A pharmaceutical composition comprising an IgM antibody or its fragment that specifically binds to a therapeutic antibody, with a molar ratio of 5:1 to 1:10, enhancing the therapeutic antibody's efficacy by prolonging its half-life and stabilizing its effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic mouse models are used to study autoimmunity, then research on autoimmune diseases can be conducted, but the models do not accurately represent human autoimmune diseases and fail to consider the role of natural polyreactive IgM antibodies
Solution Approach 1:
The patent introduces natural polyreactive IgM antibodies as an intermediary element that mediates between the therapeutic IgG antibody and the autoimmune disease pathology. These IgM antibodies specifically bind to therapeutic IgG antibodies, modulating their activity and providing a more accurate representation of human autoimmune disease mechanisms that transgenic models fail to capture.
2Duration of action of moving object
If therapeutic antibodies are administered alone, then treatment of autoimmune diseases can be provided, but the half-life and stability of the therapeutic antibody are limited
Solution Approach 1:
The patent combines therapeutic IgG antibodies with natural polyreactive IgM antibodies in a unified treatment regimen. The IgM antibodies bind to the therapeutic IgG antibodies, forming immune complexes that are cleared more slowly from circulation, thereby extending the half-life and stabilizing the therapeutic effect of the IgG antibody.
Solution Approach 2:
The patent employs preliminary action by administering or preparing IgM antibodies that will bind to therapeutic IgG antibodies before or during treatment. This pre-established binding relationship ensures prolonged circulation time and enhanced stability of the therapeutic antibody from the outset of treatment.
3Reliability
If natural polyreactive IgM antibodies are considered in therapy, then treatment outcomes for autoimmune diseases can be improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent leverages the body's own natural polyreactive IgM antibodies rather than introducing exogenous complex molecules. The endogenous IgM antibodies naturally bind to therapeutic IgG antibodies, providing the desired prolongation effect without requiring complex external intervention systems or multiple administered components.
Data Source
AI summary
The invention relates to a pharmaceutical composition comprising an IgM antibody or a fragment thereof and a therapeutic antibody, wherein the IgM antibody specifically binds to the therapeutic antibody. The invention further relates to a method of treatment of a disease or disorder, the method comprising the steps of: a) administering an effective dose of a therapeutic antibody; and b) administering a corresponding dose of an IgM antibody or a fragment thereof, wherein the IgM antibody specifically binds to the therapeutic antibody.